765 related articles for article (PubMed ID: 17561232)
21. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Horan JT; Francis CW
Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689
[TBL] [Abstract][Full Text] [Related]
22. A neoantigenic determinant in coiled coil region of human fibrin beta-chain.
Lugovskoy EV; Gritsenko PG; Kolesnikova IN; Lugovskaya NE; Komisarenko SV
Thromb Res; 2009 Mar; 123(5):765-70. PubMed ID: 18977516
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies.
Bini A; Mesa-Tejada R; Fenoglio JJ; Kudryk B; Kaplan KL
Lab Invest; 1989 Jun; 60(6):814-21. PubMed ID: 2659890
[TBL] [Abstract][Full Text] [Related]
24. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
Bini A; Itoh Y; Kudryk BJ; Nagase H
Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
[TBL] [Abstract][Full Text] [Related]
25. [Molecular marker for detecting hypercoagulable state].
Magari Y; Mizunaga S; Ito M; Shibata T; Ito H
Rinsho Byori; 1994 Jan; 42(1):22-33. PubMed ID: 8107279
[TBL] [Abstract][Full Text] [Related]
26. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
Dyr JE; Cajthamlová H; Suttnar J
Cas Lek Cesk; 1990 Oct; 129(43):1349-51. PubMed ID: 2249231
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibodies specific for a conformationally altered state of fibrinogen.
Zamarron C; Ginsberg MH; Plow EF
Thromb Haemost; 1990 Aug; 64(1):41-6. PubMed ID: 1703332
[TBL] [Abstract][Full Text] [Related]
28. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.
Dempfle CE
Thromb Haemost; 1999 Aug; 82(2):673-83. PubMed ID: 10605767
[TBL] [Abstract][Full Text] [Related]
29. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
McCarron BI; Marder VJ; Francis CW
Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
[TBL] [Abstract][Full Text] [Related]
30. A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
Gargan PE; Ploplis VA; Scheu JD
Thromb Haemost; 1988 Jun; 59(3):426-31. PubMed ID: 3142080
[TBL] [Abstract][Full Text] [Related]
31. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma.
Koppert PW; Hoegee-de Nobel E; Nieuwenhuizen W
Thromb Haemost; 1988 Apr; 59(2):310-5. PubMed ID: 3133813
[TBL] [Abstract][Full Text] [Related]
32. Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain.
Odrljin TM; Rybarczyk BJ; Francis CW; Lawrence SO; Hamaguchi M; Simpson-Haidaris PJ
Biochim Biophys Acta; 1996 Nov; 1298(1):69-77. PubMed ID: 8948490
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
[TBL] [Abstract][Full Text] [Related]
34. Disseminated intravascular coagulation (DIC).
Mammen EF
Clin Lab Sci; 2000; 13(4):239-45. PubMed ID: 11586511
[TBL] [Abstract][Full Text] [Related]
35. Soluble fibrin augments spreading of fibroblasts by providing RGD sequences of fibrinogen in soluble fibrin.
Yang W; Wu B; Asakura S; Kohno I; Matsuda M
Thromb Res; 2004; 114(4):293-300. PubMed ID: 15381393
[TBL] [Abstract][Full Text] [Related]
36. Fibrin degradation products. A review of structures found in vitro and in vivo.
Gaffney PJ
Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
[TBL] [Abstract][Full Text] [Related]
37. Clinical implication of plasma level of soluble fibrin monomer-fibrinogen complex in patients with abdominal aortic aneurysm.
Hosaka A; Miyata T; Aramoto H; Shigematsu H; Nakazawa T; Okamoto H; Shigematsu K; Nagawa H
J Vasc Surg; 2005 Aug; 42(2):200-5. PubMed ID: 16102614
[TBL] [Abstract][Full Text] [Related]
38. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.
Elms MJ; Bunce IH; Bundesen PG; Rylatt DB; Webber AJ; Masci PP; Whitaker AN
Thromb Haemost; 1983 Aug; 50(2):591-4. PubMed ID: 6356456
[TBL] [Abstract][Full Text] [Related]
39. Two monoclonal antibodies to D-dimer-specific inhibitors of fibrin polymerization.
Lugovskoy EV; Gritsenko PG; Kolesnikova IN; Zolotarova EN; Chernishov VI; Nieuwenhuizen W; Komisarenko SV
Thromb Res; 2004; 113(3-4):251-9. PubMed ID: 15140590
[TBL] [Abstract][Full Text] [Related]
40. Markers of fibrinogen derivatives used in clinical investigation.
Soria J; Soria C; Mirshahi M; Samama MM
Semin Thromb Hemost; 1985 Apr; 11(2):129-32. PubMed ID: 2412296
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
